These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9345401)

  • 21. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T; Sölberg Sørensen P; Rice G
    J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
    Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolving management of optic neuritis and multiple sclerosis.
    Arnold AC
    Am J Ophthalmol; 2005 Jun; 139(6):1101-8. PubMed ID: 15953446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How much can we learn from long-term extension trials in multiple sclerosis?
    Noseworthy JH
    Neurology; 2006 Sep; 67(6):930-1. PubMed ID: 17000954
    [No Abstract]   [Full Text] [Related]  

  • 27. Interferon-beta1a treatment for multiple sclerosis.
    Sandberg-Wollheim M
    Expert Rev Neurother; 2005 Jan; 5(1):25-34. PubMed ID: 15853471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis].
    Nervenarzt; 1999 Apr; 70(4):371-86. PubMed ID: 10355003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study.
    Freedman MS; Forrestal FG
    Mult Scler; 2008 Nov; 14(9):1234-41. PubMed ID: 18632774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interferon beta-1b in multiple sclerosis--news regarding open questions].
    Nervenarzt; 1997 Aug; 68(8 Suppl Interferon):1-4. PubMed ID: 9380220
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.
    Kobelt G; Jönsson L; Miltenburger C; Jönsson B
    Int J Technol Assess Health Care; 2002; 18(1):127-38. PubMed ID: 11987436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial].
    Fernández O; Antigüedad A; Arbizu T; Burgués S; Capdevila A; de Castro P; Correa de Sá JC; García-Merino JA; Izquierdo G; Magalhaes A; Montalbán X; Zarranz JJ
    Rev Neurol; 1999 Dec 16-31; 29(12):1093-9. PubMed ID: 10652728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and disease modifying treatments in multiple sclerosis.
    Zajicek J
    Postgrad Med J; 2005 Sep; 81(959):556-61. PubMed ID: 16143683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of multiple sclerosis. The present and the future. Study Group on Diagnosis and Therapy of Multiple Sclerosis].
    Cazzato G; Antonello RM; Zorzon M; Torre P; Zivadinov R; Moretti R; Bragadin LM; De Masi R; Nasuelli D
    Recenti Prog Med; 1999 Oct; 90(10):538-44. PubMed ID: 10592740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon beta: the current position.
    Boothman BR
    Br J Hosp Med; 1997 Mar 19-Apr 1; 57(6):277-80. PubMed ID: 9196574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Preventive treatment of multiple sclerosis. Rules for treatment with immunomodulators].
    Izquierdo G
    Rev Neurol; 2002 Dec 1-15; 35(11):1094-9. PubMed ID: 12497317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [EDMUS--a new European databank for multiple sclerosis. A brief introduction of ongoing and planned multicenter studies within the scope of the "European Concentrated Action for Multiple Sclerosis"].
    Flachenecker P; Hartung HP
    Nervenarzt; 1996 Apr; 67(4):277-82. PubMed ID: 8684505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neurorehabilitation of multiple sclerosis].
    Cáceres FJ
    Rev Neurol; 2000 Sep 1-15; 31(5):477-81. PubMed ID: 11027102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.